Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 42,266,528 shares, a decrease of 7.6% from the August 31st total of 45,757,204 shares. Based on an average daily volume of 30,475,195 shares, the short-interest ratio is presently 1.4 days.

Several institutional investors have recently made changes to their positions in TEVA. San Francisco Sentry Investment Group CA acquired a new position in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter valued at $106,000. Kistler Tiffany Companies LLC increased its holdings in shares of Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after acquiring an additional 1,571 shares during the period. FNY Managed Accounts LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited in the 1st quarter valued at $123,000. Bronfman E.L. Rothschild L.P. increased its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after acquiring an additional 94 shares during the period. Finally, Sterling Investment Advisors Ltd. increased its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after acquiring an additional 100 shares during the period. 56.77% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on TEVA shares. TheStreet cut shares of Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research report on Friday, August 25th. ValuEngine cut shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Deutsche Bank AG reaffirmed a “buy” rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Credit Suisse Group cut shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $25.00 to $13.00 in a research report on Wednesday, August 23rd. Finally, Barclays PLC lowered their price target on shares of Teva Pharmaceutical Industries Limited from $38.00 to $23.00 and set an “equal weight” rating for the company in a research report on Monday, August 7th. Four research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $30.39.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 16.08 on Thursday. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $45.85. The firm’s market cap is $16.34 billion. The stock has a 50 day moving average of $16.99 and a 200-day moving average of $26.97.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.25 earnings per share. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.31 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th were issued a $0.085 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.11%. Teva Pharmaceutical Industries Limited’s payout ratio is -15.36%.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/10/05/short-interest-in-teva-pharmaceutical-industries-limited-teva-declines-by-7-6.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.